Amgen Inc. Faces a Mild Decline Amid a Bullish Nasdaq Day

Amgen Inc. (AMGN) closed the trading session on 9 July 2026 at $367.99, down 2.06 % from the previous close, a modest decline that mirrors the broader market’s mixed performance. The decline occurred as the Nasdaq index rose 1.12 %, reaching 26 121.16, while the Dow Jones Industrial Average edged up 0.29 % to 53 061.30.

Market Context

The U.S. equities market recorded a record high for the Dow for the first time, buoyed by gains in heavyweight names such as Boeing, IBM and Goldman Sachs. Within the technology and biopharma segments, leaders like Tesla, AMD and Qualcomm posted double‑digit gains, whereas Amgen’s share price slipped slightly, aligning with the modest downward pressure on the broader health‑care sector.

Company Snapshot

  • Industry: Biotechnology
  • Primary Exchange: Nasdaq
  • Market Capitalization: $198.67 billion
  • Price‑to‑Earnings Ratio: 25.53
  • 52‑Week Range: $269.77 – $391.29

Amgen’s valuation metrics and market cap place it among the larger players in the biotech arena, with a solid earnings multiple that reflects investor expectations for continued growth in its therapeutic pipeline.

Recent Regulatory Developments

While Amgen’s stock saw a slight dip, the broader biopharma landscape benefited from significant regulatory news. On 9 July 2026, the U.S. Food and Drug Administration approved ENNUMO™ (pegfilgrastim‑pccg), a biosimilar to NEULASTA® by Accord BioPharma. This approval broadened the portfolio of granulocyte colony‑stimulating factor (G‑CSF) biosimilars in the U.S. market, potentially intensifying competition in the oncology support‑therapy space. Although this development directly involves Accord BioPharma, it underscores the dynamic regulatory environment that Amgen and its peers operate within.

Outlook

Amgen’s modest decline today does not signal a fundamental shift in its strategic trajectory. The company remains focused on discovering, developing, manufacturing, and marketing medicines for grave illnesses, with a strong emphasis on human therapeutics and innovations rooted in cellular and molecular biology. Investors will likely monitor upcoming clinical milestones and regulatory filings for further guidance on the company’s performance.

The information above is compiled from the latest market data and press releases available as of 9 July 2026.